Skip to content

Ultrasound and Mammography for Screening Breast Cancer in Chinese Women

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01880853
Enrollment
47709
Registered
2013-06-19
Start date
2008-11-30
Completion date
2011-12-31
Last updated
2013-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

breast cancer, screening, mammography, ultrasound

Brief summary

Early detection of breast cancer through screening has been a common practice in the United States and several European countries for decades.It is effective in reducing the mortality of breast cancer and improving the postoperative quality of life of patients. Mammography has been the standard imaging method for the screening, and in recent years, a supplemental ultrasound exam is also recommended.A prospective, multi-center, randomized trial is needed to define an optimal screening strategy that suits Chinese women and the socioeconomics of China.

Interventions

OTHERmammography

participants were screened by mammography alone every year

OTHERultrasound

participants were screened by ultrasound alone every year

Participants were screened by both mammography and ultrasound every year

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Written informed consent; * residence from community or working units

Exclusion criteria

* pregnancy; * lactation; * known metastatic cancer; * signs or symptoms of breast disease; * presence of breast implants, breast surgery within prior 12 months; * had mammography or ultrasound exam within prior 12 months * males.

Design outcomes

Primary

MeasureTime frameDescription
screening yield3 yearsSensitivities, specificities, positive predictive values, and negative predictive values

Secondary

MeasureTime frameDescription
Cost-effectiveness3 yearscost of each screening modility to detect one cancer

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026